In this randomized controlled trial involving pediatric patients, fremanezumab led to greater reductions in the number of migraine days per month versus placebo, consistent with previous trials in ...
Illumina’s Billion Cell Atlas aims to standardize massive CRISPR perturbation data to make biological response patterns more ...
Injuries suffered at high elevations are associated with a significantly higher odds of developing deep vein thrombosis (DVT) ...
Anthropic is packaging Claude as a governed healthcare workflow tool aimed at documentation, prior authorization, and other ...
Duloxetine is significantly more effective than placebo at reducing refractory chronic cough (RCC) frequency and sensitivity.
AstraZeneca is acquiring Modella AI to embed multimodal foundation models into oncology R&D and strengthen biomarker driven ...
NVIDIA and Eli Lilly plan to invest up to $1B over five years in a joint AI lab to tighten the loop between model building ...
Lyme disease (LD) is associated with substantial health care costs, with per-patient direct costs consistently high across ...
NVIDIA and Lilly put $1B behind AI as core drug infrastructure During the JPMorgan Healthcare Conference week in mid January ...
Ethosuximide was not superior to placebo for the treatment of abdominal pain in adults with irritable bowel syndrome. Evidence Rating Level: 1 (Excellent) Previous research suggested that increased ...
Compared to placebo, edaravone dexborneol improved functional independence at 90 days in patients with acute ischaemic stroke who underwent endovascular thrombectomy. Evidence Rating Level: 1 ...
New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, including phased data submission to support earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results